These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16583487)

  • 1. Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-alpha.
    Fitch PG; Cron RQ
    J Rheumatol; 2006 Apr; 33(4):825; author reply 826-7. PubMed ID: 16583487
    [No Abstract]   [Full Text] [Related]  

  • 2. Septic arthritis caused by Actinobacillus ureae in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha therapy.
    Kaur PP; Derk CT; Chatterji M; Dehoratius RJ
    J Rheumatol; 2004 Aug; 31(8):1663-5. PubMed ID: 15290751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept.
    Elwood RL; Pelszynski MM; Corman LI
    Pediatr Infect Dis J; 2003 Mar; 22(3):286-8. PubMed ID: 12664882
    [No Abstract]   [Full Text] [Related]  

  • 4. Borreliosis in a patient treated with anti-TNFα therapy: first case.
    Bonnet N; Guis S; Drancourt M; Brouqui P; Berbis P
    J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):367-8. PubMed ID: 20524947
    [No Abstract]   [Full Text] [Related]  

  • 5. Parapharyngeal abscess in a patient receiving etanercept.
    Borrás-Blasco J; Nuñez-Cornejo C; Gracia-Perez A; Rosique-Robles JD; Casterá MD; Viosca E; Abad FJ
    Ann Pharmacother; 2007 Feb; 41(2):341-4. PubMed ID: 17227824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis.
    Spadaro A; Ceccarelli F; Scrivo R; Valesini G
    Ann Rheum Dis; 2008 Nov; 67(11):1650-1. PubMed ID: 18854519
    [No Abstract]   [Full Text] [Related]  

  • 7. Relapsing oligoarticular septic arthritis during etanercept treatment of rheumatoid arthritis.
    Mor A; Mitnick HJ; Greene JB; Azar N; Budnah R; Fetto J
    J Clin Rheumatol; 2006 Apr; 12(2):87-9. PubMed ID: 16601543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?
    Khanna D; McMahon M; Furst DE
    Arthritis Rheum; 2004 Apr; 50(4):1040-50. PubMed ID: 15077286
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy.
    Mangge H; Gindl S; Kenzian H; Schauenstein K
    J Rheumatol; 2003 Nov; 30(11):2506-7. PubMed ID: 14677200
    [No Abstract]   [Full Text] [Related]  

  • 12. Taiwan experience with etanercept in juvenile rheumatoid arthritis.
    Lai JH
    J Microbiol Immunol Infect; 2005 Dec; 38(6):451-4. PubMed ID: 16341348
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis.
    Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Chon Y; Zhang N; Baumgartner SW
    Arthritis Rheum; 2010 Nov; 62(11):3259-64. PubMed ID: 20669280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate.
    Sweet DD; Isac G; Morrison B; Fenwick J; Dhingra V
    CJEM; 2007 Jan; 9(1):40-2. PubMed ID: 17391602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory idiopathic thrombocytopenic purpura treated with the soluble tumor necrosis factor receptor etanercept.
    Litton G
    Am J Hematol; 2008 Apr; 83(4):344. PubMed ID: 18186526
    [No Abstract]   [Full Text] [Related]  

  • 17. Etanercept in psoriasis treatment.
    Pietrzak A; Chodorowska G; Urban J; Roliński J; Pietrzak B
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):222-6. PubMed ID: 15314989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are glucocorticoids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept?
    Luzi G; Laganà B; Salemi S; Di Rosa R
    Clin Ter; 2009; 160(2):121-3. PubMed ID: 19452100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis].
    Pontikaki I; Gerloni V; Gattinara M; Luriati A; Salmaso A; De Marco G; Teruzzi B; Valcamonica E; Fantini F
    Reumatismo; 2006; 58(1):31-8. PubMed ID: 16639486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.